What type of study is this?

Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study

View Full Paper

Ask AI

Bookmark

Colchicine use does not significantly reduce the risk of major adverse cardiovascular events compared to NSAIDs.
The PS-matched hazard ratio for major adverse cardiovascular events was 0.94, indicating no significant difference.
A nationwide cohort study over 11 years evaluated patients with gout and T2DM using claims data.
Findings suggest colchicine may not be effective for reducing cardiovascular risks among patients with T2DM and gout.

No takes yet. Share an insight, caveat, or question.

Nationwide cohort study reveals no significant reduction in major adverse cardiovascular events with colchicine compared to NSAIDs in T2DM patients.

Jeon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Nationwide cohort study reveals no significant reduction in major adverse cardiovascular events with colchicine compared to NSAIDs in T2DM patients.